IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL5.94▲ 0.05% USD/MXN19.06▼ 0.11% USD/CLP1,017▲ 0.04% USD/COP3,422▲ 1.93% USD/PEN3.45▼ 0.04% USD/ARS1,562▼ 0.18% USD/UYU40.61▲ 3.19% USD/PYG6,212▲ 2.34% USD/BOB11.64▲ 2.55% USD/DOP59.52▼ 0.80% USD/CRC441.73▲ 2.68% USD/GTQ7.64▲ 3.22% USD/HNL26.89▲ 3.31% USD/NIO36.62▲ 0.34% USD/VES913.46▼ 0.45% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.60% USD/TTD6.70▲ 2.00% EUR/BRL6.52▲ 1.20% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74% IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL 5.94 ▲ 0.01% USD/MXN 19.06 ▼ 0.13% USD/CLP 1,016 ▼ 0.09% USD/COP 3,428 ▲ 2.10% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,565 ▲ 0.01% USD/UYU 40.61 ▲ 3.16% USD/PYG 6,212 ▲ 2.34% USD/BOB 11.64 ▲ 3.02% USD/DOP 59.52 ▼ 0.80% USD/CRC 441.73 ▲ 2.68% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.89 ▲ 3.31% USD/NIO 36.62 ▲ 0.34% USD/VES 913.46 ▼ 0.45% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 2.60% USD/TTD 6.70 ▲ 2.00% EUR/BRL 6.52 ▲ 1.16% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74%
since 2009
Friday, November 20, 2026

Covid-19 Brazil

Ivermectin May Reduce Risk of Covid-19 Death by Up to 75% – Unverified Meta-analysis

By · · 3 min read
A study, not yet peer-reviewed, conducted by researchers from 12 countries suggests that the antiparasitic could play an important role in reducing Covid-19 deaths.
A study, not yet peer-reviewed, conducted by researchers from 12 countries suggests that the antiparasitic could play an important role in reducing Covid-19 deaths.

RIO DE JANEIRO, BRAZIL – A study, not yet peer-reviewed, conducted by researchers from 12 countries, suggests that the antiparasitic drug could play an important role in reducing Covid-19 deaths.

The group conducted a study known as meta-analysis, which consists of a review of scientific articles already published on the subject worldwide. It included 18 clinical trials involving 2,282 patients.

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The finding was that Ivermectin “was associated with the reduction of inflammation markers and faster viral elimination detected in the PCR test.”

Also according to the researchers, in six studies involving moderate or severe cases of covid-19, there was a 75% reduction in mortality in patients taking Ivermectin.

The conclusions were published on January 19th on the Research Square platform and still require peer-review for scientific relevance.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Mexico's election chief won't be named before late January”

The authors themselves report that “many studies that were included [in the meta-analysis] have not yet been published or peer-reviewed,” which renders the study “subject to confusing questions”.

“Furthermore, there was a large variation in treatment patterns between trials, and the dose of Ivermectin and duration of treatment were varied. Ivermectin must be validated in appropriately controlled randomized trials before findings are sufficient for a review by regulatory authorities.”

The British newspaper Financial Times, which also reported on the study, points out that the only antiviral with any kind of approval to treat Covid-19 is Remdesivir.

The drug, an antiviral used to treat former U.S. President Donald Trump when he had the disease, has shown benefits in reducing the likelihood of hospitalization, but no effect on reducing the risk of mortality or viral load – the amount of virus circulating in the bloodstream.

Ivermectin is not an antiviral, but the results suggest that the drug may have antiviral properties. The researchers point out that the results are “encouraging”, but more studies are needed to provide robust evidence to justify its approval for the treatment of Covid-19.

“It is a drug used worldwide. The drug substance costs 12 cents. The medicine costs US$3 in India and US$960 in the United States,” said Andrew Hill – one of the researchers in the study – to the Financial Times.

He added that by reducing the viral load, Invermectin may reduce the risk of infection, as well as transmitting the disease. “If people testing positive for Covid-19 are treated immediately with a drug that eliminates the virus quickly, it may make them less infectious,” he told the newspaper. “This ‘treatment as prevention’ strategy works for HIV and should now be tested for Covid-19,” he concluded.

 

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.